

Miller Eric Alejandro
Form 3
November 09, 2018

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Miller Eric Alejandro
(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)
11/02/2018

3. Issuer Name and Ticker or Trading Symbol

ACADIA PHARMACEUTICALS INC [ACAD]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer ☐ Other
(give title below) (specify below)
Controller & PAO

C/O ACADIA
PHARMACEUTICALS
INC.,Â 3611 VALLEY CENTRE
DRIVE, SUITE 300

(Street)

SAN DIEGO,Â CAÂ 92130

(City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock

3,212

D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: Miller Eric Alejandro - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (Right to Buy)	Â (1)	05/29/2024	Common Stock	7,500	\$ 20.65	D	Â
Employee Stock Option (Right to Buy)	Â (2)	01/25/2025	Common Stock	3,900	\$ 32.28	D	Â
Employee Stock Option (Right to Buy)	Â (3)	01/05/2026	Common Stock	6,615	\$ 29.24	D	Â
Employee Stock Option (Right to Buy)	Â (4)	03/07/2027	Common Stock	7,350	\$ 36.54	D	Â
Employee Stock Option (Right to Buy)	Â (5)	09/06/2027	Common Stock	9,187	\$ 35.8	D	Â
Employee Stock Option (Right to Buy)	Â (6)	04/06/2028	Common Stock	5,570	\$ 16.5	D	Â
Employee Stock Option (Right to Buy)	Â (7)	10/14/2028	Common Stock	3,342	\$ 21.28	D	Â
Restricted Stock Units	Â (8)	Â (8)	Common Stock	1,671	\$ (9)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Miller Eric Alejandro C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO, CA 92130	Â	Â	Â Controller & PAO	Â

Signatures

/s/ Eric Alejandro
Miller 11/09/2018

**Signature of Reporting
Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option is fully vested and exercisable.

(2) 25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2016, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

(3)

Edgar Filing: Miller Eric Alejandro - Form 3

25% of the shares subject to the Stock Option vested and became exercisable on January 1, 2017, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

- (4) 25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- (5) 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- (6) 25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- (7) 25% of the shares subject to the Stock Option vest and become exercisable on October 15, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- (8) The restricted stock units vest in four equal annual installments beginning October 15, 2019.
- (9) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.